Antidepressant activity and pharmacological interactions of ciclazindol
- 21 Downloads
Ciclazindol, a new tetracyclic compound, appears to be a potentially important antidepressant of the same order as amitriptyline, but with significantly fewer, subjective side effects. Although as a group the patients treated with ciclazidol lost weight, clinical improvement was observed to be significantly corelated with the weight gain in both groups. The peripheral adrenergic interactions were studied. In the dosage used (100 mg/day) ciclazindol was observed to be a peripheral NA-reuptake blocker with no significant effect on the postsynaptic α-receptors.
Plasma concentrations of the drug were estimated and their relationship to the therapeutic outcome, side effects, and adrenergic interaction were studied.
No significant change in resting BP or ECG was observed following 4–6 weeks' treatment with ciclazindol.
Key wordsCiclazindol Antidepressant activity Subjective side effects Peripheral adrenergic interactions Plasma drug concentration
Unable to display preview. Download preview PDF.
- Alexanderson, B., Sjoqvist, F., Price-Evans, D.A: Steady-state plasma levels of nortriptyline in twine. Influence of genetic factors and drug therapy. Br. Med. J. 1969IV, 764–766Google Scholar
- Braithwaite, R.A., Goulding, R., Theano, G., Bailey, J., Coppen, A.: Plasma concentration of amitriptyline and clinical response. Lancet 1972I, 1297–1300Google Scholar
- Burns, J.H., Rand, M.J.: The actions of sympathomimetic amines in animals treated with reserpine. J. Physiol. (Lond.) 144, 314–319 (1958)Google Scholar
- Coppen, A., Gupta, R., Montgomery, S., Ghose, K., Bailey, J., Burns, B, de Ridder, J.J.: Mianserin hydrochloride: A novel antidepressant. Br. J. Psychiatry 129, 342–345 (1976)Google Scholar
- Ghose, K.: Lithium salts: therapeutic and unwanted effects. Br. J. Hosp. Med. (in press, 1977)Google Scholar
- Ghose, K., Coppen, A., Turner, P.: Autonomic actions and interactions of mianserin hydrochloride. Psychopharmacology 49, 201–204 (1976a)Google Scholar
- Ghose, K., Gifford, L.A., Turner, P., Leighton, M.: Studies of the interaction of desmethylimipramine with tyramine in man after a single oral dose and its correlation with plasma concentration. Br. J. Clin. Pharmacol. 3, 334–336 (1976b)Google Scholar
- Ghose, K., Gupta, R., Coppen, A., Lund, J.: Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients. Eur. J. Pharmacol 42, 31–37 (1977)Google Scholar
- Ghose, K., Turner, P., Coppen, A.: Intravenous tyramine pressor response in depression. Lancet 1975I, 1317–1318Google Scholar
- Hamilton, M.: A rating scale for-depression. J. Neurol. Neurosurg. Psychiatry 23, 56 (1960)Google Scholar
- Innes, I. R., Nickerson, M.: Drugs acting on postganglionic adrenergic nerve endings and structures innervated by them (sympathomimetic drugs). In: The pharmacological basis of therapeutics, 4th. ed., L.S. Goodman and A. Gilman, eds., p. 510. New York: MacMillan 1965Google Scholar
- Klerman, G.L., Cole, J.O.: Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol. Rev. 17, 101–141 (1965)Google Scholar
- Medical Research Council Clinical Psychiatry Committee (1965). Medical Research Council trial of the treatment of depressive illness. Br. Med. J. 1965I, 881–886Google Scholar
- Siwers, B., Tuck, D., Freyschuss, U., Azarnoff, D.L., Sjoqvist, F.: A novel approach to the phase I clinical trial of tricyclic antidepressant drugs. Abstract for Fourth International Congress on Pharmacology (1969)Google Scholar
- Sugden, R.F.: Action of indoramin and other compounds on the uptake of neurotransmitters into rat cortical slices. Br. J. Pharmacol. 51, 467–472 (1974)Google Scholar